Newsletters

Dear All, OHAMR (European Partnership on One Health AMR), the successor to the JPIAMR program, have announced the 2nd call ...

Dear All: As a way to pressure test your candidate compounds, PACE (Pathways to Antimicrobial Clinical Efficacy) and UKHSA (the ...

Dear All: CDC have today released an update to their 2019 threat list (i.e., an update to CDC’s priority pathogen ...

Dear All: NIAID/DMID have released their 2027 Omnibus Broad Agency Announcement (BAA) entitled “Development of Medical Interventions for Infectious Diseases.” ...

Dear All: Oh, no! Hot on the heels of the excellent talk at GAMRIC by Karen Bush in which the ...

Dear All: We need to make Pull incentives work! On this theme, our first topic for today is an opportunity ...

Dear All: Significantly strengthening our database documenting the human cost of AMR, we now have an impressive survey of mortality ...

Note: I’ve been away on holiday (see the newsletter’s postscript) and so there are multiple new items in both the ...

Dear All: An important and instructive analysis of optimal global antibiotic usage targets has just been published in Lancet Public ...

Dear All: WHO have announced a very interesting 2-h virtual dialogue on optimal evidence generation across the antibiotic R&D lifecycle! ...

Dear All: CDC have recently posted this eclectic mixture of funding opportunities that circle the globe!  Funding opportunity: CDC-RFA-CK-26-0107 Title: ...

Dear All: Without much fanfare, we have an announcement that PACCARB (the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria) ...